Abstract
Primary malignant melanoma of the uterine cervix is a rare disease with poor prognosis and high recurrence rate. We used Rigvir® as adjuvant therapy for a stage IVA patient. Tolerability, overall and progression-free survival are good.
| Original language | English |
|---|---|
| Pages (from-to) | 1538-1543 |
| Number of pages | 6 |
| Journal | Clinical Case Reports |
| Volume | 8 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 1 Aug 2020 |
Keywords*
- ECHO-7 virus
- melanoma
- oncology
- oncolytic virus
- Rigvir
- uterine cervix
Field of Science*
- 3.2 Clinical medicine
Publication Type*
- 1.1. Scientific article indexed in Web of Science and/or Scopus database
Fingerprint
Dive into the research topics of 'Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir(R) therapy: A case report'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver